Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Generic Imatinib in Chronic Phase of Chronic Myeloid Leukemia (CP-CML): Experience from a Multi-Center in China

Li Zhou, Bingcheng Liu, Jianda Hu, PhD, Jianhua Qu, Ming Hou, MD, Hui Sun, Jie Jin, MD PhD, Zhixiang Shen

Blood (2019) 134 (Supplement_1): 5914.

https://doi.org/10.1182/blood-2019-126546

Published: 2019

Journal Articles

Long-Term Safety of Dasatinib in Chinese Chronic Phase Chronic Myeloid Leukemia Patients with Imatinib-Resistance or -Intolerance: Results from a 6-Year Follow-up of a Multicenter Phase II Study

Xiaojun Huang, Qian Jiang, MD, Jianda Hu, MD PhD, Jianyong Li, Jie Jin, MD PhD, Fanyi Meng, Zhixiang Shen, MD, Ting Liu, Depei Wu, MDPhD, Jianmin Wang, Jianxiang Wang

Blood (2016) 128 (22): 1928.

https://doi.org/10.1182/blood.V128.22.1928.1928

Published: 2016

Journal Articles

Retrospective Study Evaluating Hematological Remission Rates and Survival in Chinese Adults with Relapsed or Refractory (r/r) Philadelphia Chromosome Negative (Ph - ) B-Precursor Acute Lymphoblastic Leukemia (ALL)

Jun Ma, MD, Ting Liu, MD, Jie Jin, MD PhD, Jianda Hu, MD PhD, Qifa Liu, MD, Jianxiang Wang, MD, Zhixiang Shen, MD, Xin Du, MD PhD, Bin Jiang, MD, Xianhua Meng, PhD

Blood (2016) 128 (22): 5198.

https://doi.org/10.1182/blood.V128.22.5198.5198

Published: 2016

Journal Articles

Retinoic Acid and Arsenic Trioxide with or without Chemotherapy for Acute Promyelocytie Leukemia with Different Risk Stratifications: A Interim Analysis of China APL 2012 Study

Blood (2016) 128 (22): 445.

https://doi.org/10.1182/blood.V128.22.445.445

Published: 2016

Journal Articles

The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia

Blood (2016) 128 (11): 1525–1528.

https://doi.org/10.1182/blood-2016-02-699439

Published: 2016

Includes: Supplemental data

Journal Articles

Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Yuankai Shi, MD PhD, Mei Dong, MD, Jun Zhu, MD, Daobin Zhou, MD, Huiqiang Huang, MD, Ping Tu, MD, Weijing Zhang, MD, Xiaonan Hong, MD, Xielan Zhao, MD, Jianfang Sun, MD, Yuehua Liu, MD, Lugui Qiu, MD PhD, ZhiXiang Shen, MD, Jifeng Feng, MD, Xiaoyan Ke, MD PhD

Blood (2015) 126 (23): 1513.

https://doi.org/10.1182/blood.V126.23.1513.1513

Published: 2015

Journal Articles

Long-Term Follow-up of Survival, Complications, Arsenic Retention and Quality of Life in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid/Arsenic Trioxide Combination Therapy

Hongming Zhu, Jiong Hu, Li Chen, Wei Zhou, Xiaoyang Li, Wang Lining, Xia Zhao, Yunxiang Zhang, Huijin Zhao, Yu Chen, Huiping Sun, Qiusheng Chen, Yu Chen, Weili Zhao, Jianqing Mi, Zhixiang Shen, Saijuan Chen, Zhenyi Wang, Junmin Li, MD PhD

Blood (2014) 124 (21): 282.

https://doi.org/10.1182/blood.V124.21.282.282

Published: 2014

Journal Articles

First-Line Treatment and Management of Chronic Myeloid Leukemia (CML) in Clinical Practice: Update of > 1800 Patients (Pts) in the WORLD CML Registry

Jorge E. Cortes, MD, Ricardo Pasquini, Hagop M. Kantarjian, MD, David Joske, MBBS, FRCPA, FRACP, Luis A Meillon, MD, Zhixiang Shen, MD, Carmen Piccolo, MD, Oleg Zernovak, MD, Ramsathish Sivarathinasami, Dawn F. Eng, Dong-Wook Kim, Timothy P. Hughes, MD, MBBS

Blood (2012) 120 (21): 3750.

https://doi.org/10.1182/blood.V120.21.3750.3750

Published: 2012

Journal Articles

Results of a Randomized, Open-Label, Phase IIIb Study of 2 Schedules of Decitabine in Higher-Risk Myelodysplastic Syndrome Patients

Depei Wu, Xin Du, PhD, Jie Jin, MD, Zhijian Xiao, MD, Zhixiang Shen, MD, Zonghong Shao, MD, Xiao Li, MD, PhD, Xiaojun Huang, Ting Liu, Li Yu, Jianyong Li, MD, PhD, Baoan Chen, Guangsheng He, Zhen Cai, Changgeng Ruan, MD., PhD.

Blood (2012) 120 (21): 3846.

https://doi.org/10.1182/blood.V120.21.3846.3846

Published: 2012

Journal Articles

A Multicenter, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Posaconazole Vs Fluconazole in the Prophylaxis of Invasive Fungal Infection in a Chinese Population

Shen Yang, MD, Xiaojun Huang, Jianxiang Wang, MD, Jie Jin, PhD, Jianda Hu, PhD, Kang Yu, Depei Wu, MD, Shujie Wang, MD, PhD, Li Yu, Xiequn Chen, Ting Liu, MD, Yingmin Liang, Chen Fangping, MD, Yan Li, MD, Zhixiang Shen, MD, PhD

Blood (2011) 118 (21): 4916.

https://doi.org/10.1182/blood.V118.21.4916.4916

Published: 2011

Journal Articles

A Multicenter, Open-Label Study of Posaconazole Oral Suspension in Treatment of Patients with Invasive Fungal Infection Refractory to or Intolerant of First-Line Therapy,

Xiaojun Huang, Fengrong Wang, Yuhong Chen, MD, PhD, Ting Liu, MD, Jianxiang Wang, MD, Jianda Hu, PhD, Jie Jin, MD, Fangping Chen, Shujie Wang, MD, PhD, Zhixiang Shen, MD, PhD, Li Yu, Kang Yu, Yingmin Liang

Blood (2011) 118 (21): 3241.

https://doi.org/10.1182/blood.V118.21.3241.3241

Published: 2011

Journal Articles

Phase 2 Study of Dasatinib in Chinese Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) or Advanced Phase Who Are Resistant to or Intolerant of Imatinib (IM)

Jianxiang Wang, MD, Xiaojun Huang, Jianda Hu, PhD, Jianyong Li, MD, PhD, Jie Jin, MD, Fanyi Meng, MD, Zhixiang Shen, MD, Ting Liu, MD, Depei Wu, MD, Jianmin Wang

Blood (2011) 118 (21): 4434.

https://doi.org/10.1182/blood.V118.21.4434.4434

Published: 2011

Journal Articles

Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Philipp D. le Coutre, MD, Bernadeta Ceglarek, Anna Turkina, Dong-Wook Kim, MD, PhD, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, David A Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Ellison Dial, MBA, Franck Emmanuel Nicolini, MD, PhD

Blood (2009) 114 (22): 1115.

https://doi.org/10.1182/blood.V114.22.1115.1115

Published: 2009

Journal Articles

Survival Outcomes of Hematopoietic Stem Cell Transplantation (HSCT) and Imatinib in the Treatment of Chronic Myeloid Leukemia Treatment in China: a Meta-Analysis.

Xiaojun Huang, MD, PhD, Zhixiang Shen, MD, PhD, Zi Chen, Yang Cao, MD, Ph.D., Xiaoping Xu, MD, Ph.D., Qiang Wang, Ph.D., Samara Mendes de Costa, Henry Dummett, Jie Chen, MD, Ph.D.

Blood (2009) 114 (22): 2497.

https://doi.org/10.1182/blood.V114.22.2497.2497

Published: 2009

Journal Articles

Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Philipp D. le Coutre, MD, Anna Turkina, Dong-Wook Kim, MD, PhD, Bernadeta Ceglarek, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, Pedro Enrique Dorlhiac-Llacer, David A Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Si-Tien Wang, Franck Emmanuel Nicolini, MD, PhD

Blood (2009) 114 (22): 3286.

https://doi.org/10.1182/blood.V114.22.3286.3286

Published: 2009

Journal Articles

Cost-Effectiveness of Imatinib in Comparison with Bone Marrow Transplant in Chronic Phase (CP) Chronic Myeloid Leukaemia (CML) in China.

Zhixiang Shen, MD, PhD, Xiaojun Huang, MD, PhD, Samara Mendes de Costa, Zi Chen, Xiaoping Xu, MD, Ph.D., Qiang Wang, Ph.D., Jie Chen, MD, Ph.D.

Blood (2009) 114 (22): 2474.

https://doi.org/10.1182/blood.V114.22.2474.2474

Published: 2009

Journal Articles

A Worldwide Observational Registry Collecting Longitudinal Data On the Management of CML Patients (The WORLD CML Registry) - Summary of the First 1001 Patients.

Ricardo Pasquini, MD, Jorge Cortes-Franco, MD, Hagop M. Kantarjian, MD, David Joske, MBBS, FRCPA, FRACP, Zhixiang Shen, MD, PhD, Luis Meillon, MD, Lidia Mongay, MD, PhD, MBA, Dawn F. Eng, Jim Wang, PhD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD

Blood (2009) 114 (22): 4267.

https://doi.org/10.1182/blood.V114.22.4267.4267

Published: 2009

Journal Articles

Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or —Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Franck Emmanuel Nicolini, MD, PhD, Dong-Wook Kim, MD, PhD, Bernadeta Ceglarek, Anna Turkina, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, Pedro Enrique Dorlhiac-Llacer, David A. Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Christine Bieri, MBA, Philipp D. le Coutre, MD

Blood (2009) 114 (22): 2201.

https://doi.org/10.1182/blood.V114.22.2201.2201

Published: 2009

Journal Articles

Clinical Efficacy of Pegylated Liposomal Doxorubicin, Vincristine and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Wen Wu, Xiaodong Gao, Lan Xu, Hua Yan, Zhixiang Shen, Jiong Hu, MD

Blood (2008) 112 (11): 5212.

https://doi.org/10.1182/blood.V112.11.5212.5212

Published: 2008

Journal Articles

The Incidence and Outcome of Acute Lymphoblastic Leukemia in Shanghai, China Over 5 Years (2002–2006)

Xiong Ni, Zhixiang Shen, Fangyuan Chen, Hui Liang, Fengjuan Lu, Jingyan Tang, Chun Wang, Jingbo Shao, Jian Hou, Shanhua Zou, Jianmin Wang

Blood (2008) 112 (11): 3946.

https://doi.org/10.1182/blood.V112.11.3946.3946

Published: 2008

NARROW

Efficacy and Safety of Generic Imatinib in Chronic Phase of Chronic Myeloid Leukemia (CP-CML): Experience from a Multi-Center in China

Long-Term Safety of Dasatinib in Chinese Chronic Phase Chronic Myeloid Leukemia Patients with Imatinib-Resistance or -Intolerance: Results from a 6-Year Follow-up of a Multicenter Phase II Study

Retrospective Study Evaluating Hematological Remission Rates and Survival in Chinese Adults with Relapsed or Refractory (r/r) Philadelphia Chromosome Negative (Ph - ) B-Precursor Acute Lymphoblastic Leukemia (ALL)

Retinoic Acid and Arsenic Trioxide with or without Chemotherapy for Acute Promyelocytie Leukemia with Different Risk Stratifications: A Interim Analysis of China APL 2012 Study

The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia

Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Long-Term Follow-up of Survival, Complications, Arsenic Retention and Quality of Life in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid/Arsenic Trioxide Combination Therapy

First-Line Treatment and Management of Chronic Myeloid Leukemia (CML) in Clinical Practice: Update of > 1800 Patients (Pts) in the WORLD CML Registry

Results of a Randomized, Open-Label, Phase IIIb Study of 2 Schedules of Decitabine in Higher-Risk Myelodysplastic Syndrome Patients

A Multicenter, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Posaconazole Vs Fluconazole in the Prophylaxis of Invasive Fungal Infection in a Chinese Population

A Multicenter, Open-Label Study of Posaconazole Oral Suspension in Treatment of Patients with Invasive Fungal Infection Refractory to or Intolerant of First-Line Therapy,

Phase 2 Study of Dasatinib in Chinese Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) or Advanced Phase Who Are Resistant to or Intolerant of Imatinib (IM)

Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Survival Outcomes of Hematopoietic Stem Cell Transplantation (HSCT) and Imatinib in the Treatment of Chronic Myeloid Leukemia Treatment in China: a Meta-Analysis.

Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Cost-Effectiveness of Imatinib in Comparison with Bone Marrow Transplant in Chronic Phase (CP) Chronic Myeloid Leukaemia (CML) in China.

A Worldwide Observational Registry Collecting Longitudinal Data On the Management of CML Patients (The WORLD CML Registry) - Summary of the First 1001 Patients.

Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or —Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Clinical Efficacy of Pegylated Liposomal Doxorubicin, Vincristine and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

The Incidence and Outcome of Acute Lymphoblastic Leukemia in Shanghai, China Over 5 Years (2002–2006)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only